| Summary of Net Revenue, Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, interest expense, and income tax (expense) benefit for the three months and nine months ended August 31, 2020 and August 31, 2019:
|
|
|
For the three
months ended
August 31,
2020
|
|
|
For the three
months ended
August 31,
2019
|
|
|
Net revenue
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
7,914,732
|
|
|
$
|
8,029,797
|
|
|
PrepaCyte®-CB
|
|
|
82,800
|
|
|
|
33,035
|
|
|
Public cord blood banking
|
|
|
116,826
|
|
|
|
160,561
|
|
|
Total net revenue
|
|
$
|
8,114,358
|
|
|
$
|
8,223,393
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
1,911,141
|
|
|
$
|
2,240,257
|
|
|
PrepaCyte®-CB
|
|
|
55,021
|
|
|
|
25,180
|
|
|
Public cord blood banking
|
|
|
394,162
|
|
|
|
323,898
|
|
|
Total cost of sales
|
|
$
|
2,360,324
|
|
|
$
|
2,589,335
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
35,616
|
|
|
$
|
38,223
|
|
|
PrepaCyte®-CB
|
|
|
6,894
|
|
|
|
9,063
|
|
|
Public cord blood banking
|
|
|
—
|
|
|
|
—
|
|
|
Total depreciation and amortization
|
|
$
|
42,510
|
|
|
$
|
47,286
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
2,736,798
|
|
|
$
|
2,175,563
|
|
|
PrepaCyte®-CB
|
|
|
21,291
|
|
|
|
(19,146
|
)
|
|
Public cord blood banking
|
|
|
(277,868
|
)
|
|
|
(163,336
|
)
|
|
Total operating income
|
|
$
|
2,480,221
|
|
|
$
|
1,993,081
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
338,675
|
|
|
$
|
413,942
|
|
|
PrepaCyte®-CB
|
|
|
—
|
|
|
|
—
|
|
|
Public cord blood banking
|
|
|
—
|
|
|
|
—
|
|
|
Total interest expense
|
|
$
|
338,675
|
|
|
$
|
413,942
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
151,570
|
|
|
$
|
498,748
|
|
|
PrepaCyte®-CB
|
|
|
—
|
|
|
|
—
|
|
|
Public cord blood banking
|
|
|
—
|
|
|
|
—
|
|
|
Total income tax expense
|
|
$
|
151,570
|
|
|
$
|
498,748
|
|
|
|
|
For the nine
months ended
August 31,
2020
|
|
|
For the nine
months ended
August 31,
2019
|
|
|
Net revenue
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
22,921,922
|
|
|
$
|
23,246,521
|
|
|
PrepaCyte®-CB
|
|
|
200,507
|
|
|
|
70,795
|
|
|
Public cord blood banking
|
|
|
484,547
|
|
|
|
529,041
|
|
|
Total net revenue
|
|
$
|
23,606,976
|
|
|
$
|
23,846,357
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
5,932,655
|
|
|
$
|
6,497,788
|
|
|
PrepaCyte®-CB
|
|
|
128,154
|
|
|
|
189,806
|
|
|
Public cord blood banking
|
|
|
1,283,202
|
|
|
|
996,259
|
|
|
Total cost of sales
|
|
$
|
7,344,011
|
|
|
$
|
7,683,853
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
109,351
|
|
|
$
|
132,409
|
|
|
PrepaCyte®-CB
|
|
|
20,683
|
|
|
|
27,191
|
|
|
Public cord blood banking
|
|
|
—
|
|
|
|
—
|
|
|
Total depreciation and amortization
|
|
$
|
130,034
|
|
|
$
|
159,600
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
6,229,222
|
|
|
$
|
6,307,426
|
|
|
PrepaCyte®-CB
|
|
|
51,671
|
|
|
|
(164,141
|
)
|
|
Public cord blood banking
|
|
|
(799,416
|
)
|
|
|
(2,799,978
|
)
|
|
Total operating income
|
|
$
|
5,481,477
|
|
|
$
|
3,343,307
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
1,069,345
|
|
|
$
|
1,245,154
|
|
|
PrepaCyte®-CB
|
|
|
—
|
|
|
|
—
|
|
|
Public cord blood banking
|
|
|
—
|
|
|
|
—
|
|
|
Total interest expense
|
|
$
|
1,069,345
|
|
|
$
|
1,245,154
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
783,960
|
|
|
$
|
654,358
|
|
|
PrepaCyte®-CB
|
|
|
—
|
|
|
|
—
|
|
|
Public cord blood banking
|
|
|
—
|
|
|
|
—
|
|
|
Total income tax expense
|
|
$
|
783,960
|
|
|
$
|
654,358
|
|
The following table shows the assets by segment as of August 31, 2020 and November 30, 2019:
|
|
|
As of
August 31,
2020
|
|
|
As of
November 30,
2019
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$
|
30,896,188
|
|
|
$
|
28,975,002
|
|
|
PrepaCyte®-CB
|
|
|
291,117
|
|
|
|
289,804
|
|
|
Public cord blood banking
|
|
|
13,252,858
|
|
|
|
13,621,354
|
|
|
Total assets
|
|
$
|
44,440,163
|
|
|
$
|
42,886,160
|
|
|